LINC00665 was validated to facilitate CRC cell growth and tumor progression via modulating miR-138-5p/SIN3A, which may offer strong evidence that LINC00665 might act as a potential therapeutic target in CRC treatment. The gene discussed is SIN3A; the disease is colorectal carcinoma.